Daiichi Sankyo Co. Ltd., of Tokyo, reported top-line results from its phase III NEUCOURSE trial testing mirogabalin in 765 Asian patients with postherpetic neuralgia. The trial met its primary endpoint with mirogabalin reducing the weekly average daily pain score from baseline to week 14 compared to placebo. Daiichi plans to present full results from NEUCOURSE and a second phase III trial, ALDAY, at an upcoming scientific conference.